|
gptkbp:instanceOf
|
gptkb:chemical_compound
|
|
gptkbp:approvalYear
|
1996
|
|
gptkbp:ATCCode
|
gptkb:C10AA05
|
|
gptkbp:bioavailability
|
14%
|
|
gptkbp:CASNumber
|
134523-00-5
|
|
gptkbp:color
|
white
|
|
gptkbp:contraindication
|
gptkb:liver_disease
pregnancy
breastfeeding
|
|
gptkbp:developedBy
|
gptkb:Pfizer
|
|
gptkbp:drugClass
|
statin
lowers cholesterol
increases HDL
reduces LDL
reduces triglycerides
|
|
gptkbp:flavor
|
bitter
|
|
gptkbp:form
|
gptkb:tablet
|
|
gptkbp:halfLife
|
14 hours
|
|
gptkbp:hasBiologicalActivity
|
inhibitor
|
|
gptkbp:hasBoxedWarning
|
not for use in pregnancy
|
|
gptkbp:hasChEMBLTargetID
|
CHEMBL4027
|
|
gptkbp:hasEliminationRoute
|
renal
biliary
|
|
gptkbp:hasInChIKey
|
XUKUURHRXDUEBC-KAYWLYCHSA-N
|
|
gptkbp:hasMolecularFormula
|
C33H35FN2O5
|
|
gptkbp:hasPatent
|
US4681893A
|
|
gptkbp:hasSMILES
|
CC(C)C1=CC=C(C=C1)C2=C(N(C3=CC=CC=C32)C)C(=O)O
|
|
gptkbp:hasUNII
|
83HN0GTJ6D
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
CHEMBL411
|
|
gptkbp:indication
|
gptkb:familial_hypercholesterolemia
prevention of cardiovascular disease
|
|
gptkbp:isApprovedDrug
|
true
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
HMG-CoA reductase inhibitor
|
|
gptkbp:metabolism
|
gptkb:CYP3A4
|
|
gptkbp:molecularWeight
|
558.64
|
|
gptkbp:name
|
gptkb:Atorvastatin
|
|
gptkbp:pregnancyCategory
|
gptkb:X_(US)
|
|
gptkbp:proteinBinding
|
98%
|
|
gptkbp:PubChem_CID
|
60823
DB01076
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
liver enzyme abnormalities
myalgia
rhabdomyolysis
|
|
gptkbp:synonym
|
gptkb:Lipitor
Atorvastatin calcium
Sortis
Torvast
|
|
gptkbp:target
|
gptkb:HMGCR
|
|
gptkbp:bfsParent
|
gptkb:montelukast
|
|
gptkbp:bfsLayer
|
6
|